Results 91 to 100 of about 50,656 (201)

Glucagon-like peptide-1 and dual/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research

Frontiers in Medicine
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has emerged as a prevalent and severe global hepatic disorder, necessitating the development of effective therapeutic strategies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), along
Xinyi Lu, Li Yang
doaj   +1 more source

Once-weekly glucagon-like peptide 1 receptor agonists.

JPMA. The Journal of the Pakistan Medical Association, 2015
The once-weekly glucagon-like peptide 1 receptor agonists (QW GLP1RA) represent a major advancement in diabetes pharmaco-therapeutics. This review describes the basic, clinical, and comparative pharmacology of this novel class of drugs. It highlights the clinical placement and posology of these drugs.
Sanjay, Kalra, Yashdeep, Gupta
openaire   +1 more source

Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature

Open Medicine
Comorbid type 2 diabetes mellitus (T2DM), severe obesity, and chronic myeloid leukemia (CML) present therapeutic challenges, especially given the limited data on glucagon-like peptide-1 (GLP-1) receptor agonists in this setting.
Zhang Yuchen, Li Anxin
doaj   +1 more source

Online Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists

JAMA Health Forum
This cross-sectional study evaluates the quality and accuracy of information presented on websites that sell compounded glucagon-like peptide-1 receptor agonists.
Chetty, Ashwin K., Chillakanti, Mahima, Ramachandran, Reshma, Ross, Joseph S., Chen, Alissa S.   +4 more
openaire   +2 more sources

Survodutide - Novel Anti Obesity Drug

JK Science
Survodutide (BI 456906) is a novel, dual agonist of glucagon and glucagon-like peptide-1 (GLP-1) receptors developed as a once-weekly subcutaneous injection for the management of obesity.
Irtiqa Ayani Rathore, Sana Malik, Amarjeet Singh, Vishal R Tandon, Annil Mahajan   +4 more
doaj  

Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders

Journal of Neurology, Neurosurgery & Psychiatry
Disease-modifying treatments for major neurocognitive disorders, including Alzheimer’s disease, Parkinson’s disease and other cognitive deficits, are among the main unmet needs in modern medicine. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for the treatment of type 2 diabetes mellitus and obesity, offer a novel ...
Riccardo De Giorgi, Ana Ghenciulescu, Courtney Yotter, Maxime Taquet, Ivan Koychev   +4 more
openaire   +3 more sources

Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches

Journal of Pharmacy & Pharmaceutical Sciences
Excess adiposity can contribute to metabolic complications, such as type 2 diabetes mellitus (T2DM), which poses a significant global health burden.
Arianne Morissette, Erin E. Mulvihill, Erin E. Mulvihill   +2 more
doaj   +1 more source

Current and potential use of GLP-1R agonists: beyond type 2 diabetes

Revista Mexicana de Endocrinología, Metabolismo y Nutrición
Intestinal incretins, glucagon-like peptide 1 (GLP-1), and gastric insulinotropic peptide, which are released after food ingestion, have glucoregulatory effects, which is why, in recent years, pharmacological agents with an impact similar to incretins ...
Graciela Zambrano-Galván, Ángel González-Romero, Miguel A. Reyes-Romero, Abelardo Camacho-Luis   +3 more
doaj   +1 more source

Glucagon-like Peptide-1 Receptor Agonists: Limitless Potential [PDF]

Doctor.Ru, 2020
T.Yu. Demidova, A.A. Kozhevnikov
openaire   +1 more source

Trends in diabetes medication prescribing from 2018 to 2021: A cross-sectional analysis.

PLoS ONE
Several new classes of medications for diabetes have recently become available newer medication classes have been increasing in use. It is unclear how their utilization varied across provinces and how the COVID-19 pandemic may have affected these trends.
Jessica Riad, Fred Abdelmalek, Noah Ivers, Mina Tadrous   +3 more
doaj   +1 more source